Ovarian cancer: new strategies and emerging targets for the treatment of patients with advanced disease

References

• Eisenhauer EA. Real-world evidence in the treatment of ovarian cancer. Ann Oncol. 2017;28(Suppl 8):viii61–5. doi:10.1093/annonc/mdx443.
   PubMedGoogle Scholar
• American Cancer Society. Cancer facts and figures 2020. https://www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-statistics/annual-cancer-facts-and-figures/2020/cancer-facts-and-figures-2020.pdf. [Accessed 2020 Nov 8].
   Google Scholar
• Monk BJ, Randall LM, Grisham RN. The evolving landscape of chemotherapy in newly diagnosed advanced epithelial ovarian cancer. Am Soc Clin Oncol Educ Book. 2019;39(39):e141–151. doi:10.1200/EDBK_239007.
   PubMedGoogle Scholar
• NCCN. National Comprehensive Cancer Network Guidelines. Ovarian cancer including fallopian tube cancer and primary peritoneal cancer. v1.2020. https://www.nccn.org/professionals/physician_gls/pdf/ovarian.pdf. Accessed 2020 Nov 8
   Google Scholar
• Bamberger ES, Perrett CW. Angiogenesis in epithelial ovarian cancer. Mol Pathol. 2002;55(6):348–359. doi:10.1136/mp.55.6.348.
   PubMedGoogle Scholar
• Ruan G, Ye L, Liu G, An J, Sehouli J, Sun P. The role of bevacizumab in targeted vascular endothelial growth factor therapy for epithelial ovarian cancer: an updated systematic review and meta-analysis. Onc Targets Ther. 2018;11:521–528. doi:10.2147/OTT.S155581.
   PubMed Web of Science ®Google Scholar
• Pujade-Lauraine E, Hilpert F, Weber B, Reuss A, Poveda A, Kristensen G, Sorio R, Vergote I, Witteveen P, Bamias A, et al. Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: the AURELIA open-label randomized phase III trial. J Clin Oncol. 2014;32(13):1302–1308. doi:10.1200/JCO.2013.51.4489.
   PubMed Web of Science ®Google Scholar
• Coleman RL, Brady MF, Herzog TJ, Sabbatini P, Armstrong DK, Walker JL, Kim BG, Fujiwara K, Tewari KS, O’Malley DM, et al. Bevacizumab and paclitaxel-carboplatin chemotherapy and secondary cytoreduction in recurrent, platinum-sensitive ovarian cancer (NRG Oncology/Gynecologic Oncology Group study GOG-0213): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol. 2017;18(6):779–791. doi:10.1016/S1470-2045(17)30279-6.
   PubMed Web of Science ®Google Scholar
• Bergers G, Hanahan D. Modes of resistance to anti-angiogenic therapy. Nat Rev Cancer. 2008;8(8):592–603. doi:10.1038/nrc2442.
   PubMed Web of Science ®Google Scholar
• Bottsford-Miller JN, Coleman RL, Sood AK. Resistance and escape from antiangiogenesis therapy: clinical implications and future strategies. J Clin Oncol. 2012;30(32):4026–4034. doi:10.1200/JCO.2012.41.9242.
   PubMed Web of Science ®Google Scholar
• Fukumura D, Kloepper J, Amoozgar Z, Duda DG, Jain RK. Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges. Nat Rev Clin Oncol. 2018;15(5):325–340. doi:10.1038/nrclinonc.2018.29.
   PubMed Web of Science ®Google Scholar
• Spannuth WA, Nick AM, Jennings NB, Armaiz-Pena GN, Mangala LS, Danes CG, Lin YG, Merritt WM, Thaker PH, Kamat AA, et al. Functional significance of VEGFR-2 on ovarian cancer cells. Int J Cancer. 2009;124(5):1045–1053. doi:10.1002/ijc.24028.
   PubMed Web of Science ®Google Scholar
• Du Bois A, Kristensen G, Ray-Coquard I, Reuss A, Pignata S, Colombo N, Denison U, Vergote I, Del CJM, Ottevanger P, et al. AGO Study Group led Gynecologic Cancer Intergroup/European Network of Gynaecologic Oncology Trials Groups Intergroup Consortium. Standard first-line chemotherapy with or without nintedanib for advanced ovarian cancer (AGO-OVAR 12): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet Oncol. 2016;17(1):78–89. doi:10.1016/S1470-2045(15)00366-6.
   PubMed Web of Science ®Google Scholar
• Miao M, Deng G, Luo S, Zhou J, Chen L, Yang J, He J, Li J, Yao J, Tan S, et al. A phase II study of apatinib in patients with recurrent epithelial ovarian cancer. Gynecol Oncol. 2018;148(2):286–290. doi:10.1016/j.ygyno.2017.12.013.
   PubMed Web of Science ®Google Scholar
• Monk BJ, Poveda A, Vergote I, Raspagliesi F, Fujiwara K, Bae DS, Oaknin A, Ray-Coquard PDM, Provencher DM, Karlan BY, et al. Anti-angiopoietin therapy with trebananib for recurrent ovarian cancer (TRINOVA-1): a randomised, multicentre, double-blind, placebo-controlled phase 3 trial. Lancet Oncol. 2014;15(8):799–808. doi:10.1016/S1470-2045(14)70244-X.
   PubMed Web of Science ®Google Scholar
• Monk BJ, Poveda A, Vergote I, Raspagliesi F, Fujiwara K, Bae DS, Oaknin A, Ray-Coquard PDM, Provencher DM, Karlan BY, et al. Final results of a phase 3 study of trebananib plus weekly paclitaxel in recurrent ovarian cancer (TRINOVA-1): long-term survival, impact of ascites, and progression-free survival-2. Gynecol Oncol. 2016;143(1):27–34. doi:10.1016/j.ygyno.2016.07.112.
   PubMed Web of Science ®Google Scholar
• Marth C, Vergote I, Scambia G, Oberaigner W, Clamp A, Berger R, Kurzeder C, Colombo N, Vuylsteke P, Lorusso D, et al. ENGOT-ov-6/TRINOVA-2: randomised, double-blind, phase 3 study of pegylated liposomal doxorubicin plus trebananib or placebo in women with recurrent partially platinum-sensitive or resistant ovarian cancer. Eur J Cancer. 2017;70:111–121. doi:10.1016/j.ejca.2016.09.004.
   PubMed Web of Science ®Google Scholar
• Vergote I, Scambia G, O’Malley DM, Van Calster B, Park SY, Del Campo JM, Meier W, Bamias A, Colombo N, Wenham RM, et al. TRINOVA-3/ENGOT-ov2/GOG-3001 investigators. Trebananib or placebo plus carboplatin and paclitaxel as first-line treatment for advanced ovarian cancer (TRINOVA-3/ENGOT-ov2/GOG-3001): a randomised, double-blind, phase 3 trial. Lancet Oncol. 2019;20(6):862–876. doi:10.1016/S1470-2045(19)30178-0.
   PubMed Web of Science ®Google Scholar
• Konstantinopoulos PA, Matulonis UA. Targeting DNA damage response and repair as a therapeutic strategy for ovarian cancer. Hematol Oncol Clin North Am. 2018;32(6):997–1010. doi:10.1016/j.hoc.2018.07.006.
   PubMed Web of Science ®Google Scholar
• Bertelsen B, Tuxen IV, Yde CW, Gabrielaite M, Torp MH, Kinalis S, Oestrup O, Rohrberg K, Spangaard I, Santoni-Rugiu E, et al. High frequency of pathogenic germline variants within homologous recombination repair in patients with advanced cancer. NPJ Genom Med. 2019;4(1):13. doi:10.1038/s41525-019-0087-6.
   PubMedGoogle Scholar
• Lopes JL, Chaudhry S, Lopes GS, Levin NK, Tainsky MA. FANCM, RAD1, CHEK1 and TP53I3 act as BRCA-like tumor suppressors and are mutated in hereditary ovarian cancer. Cancer Genet. 2019;235:57–64. doi:10.1016/j.cancergen.2019.04.061.
   PubMed Web of Science ®Google Scholar
• Farmer H, McCabe N, Lord CJ, Tutt AN, Johnson DA, Richardson TB, Santarosa M, Dillon KJ, Hickson I, Knights C, et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature. 2005;434(7035):917–921. doi:10.1038/nature03445.
   PubMed Web of Science ®Google Scholar
• Lord CJ, Ashworth A. PARP inhibitors: synthetic lethality in the clinic. Science. 2017;355(6330):1152–1158. doi:10.1126/science.aam7344.
   PubMed Web of Science ®Google Scholar
• Hoppe MM, Sundar R, Tan DSP, Jeyasekharan AD. Biomarkers for homologous recombination deficiency in cancer. J Natl Cancer Inst. 2018;110(7):704–713. doi:10.1093/jnci/djy085.
   PubMedGoogle Scholar
• Mateo J, Lord CJ, Serra V, Tutt A, Balmaña J, Castroviejo-Bermejo M, Cruz C, Oaknin A, Kaye SB, de Bono JS. A decade of clinical development of PARP inhibitors in perspective. Ann Oncol. 2019;30(9):1437–1447. doi:10.1093/annonc/mdz192.
   PubMed Web of Science ®Google Scholar
• Taylor KN, Eskander RN. PARP inhibitors in epithelial ovarian cancer. Recent Pat Anticancer Drug Discov. 2018;13(2):145–158. doi:10.2174/1574892813666171204094822.
   PubMed Web of Science ®Google Scholar
• Randall LM, Pothuri B. The genetic prediction of risk for gynecologic cancers. Gynecol Oncol. 2016;141(1):10–16. doi:10.1016/j.ygyno.2016.03.007.
   PubMed Web of Science ®Google Scholar
• Pennington KP, Walsh T, Harrell MI, Lee MK, Pennil CC, Rendi MH, Rendi MH, Thornton A, Norquist BM, Casadei S, et al. Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas. Clin Cancer Res. 2014;20(3):764–775. doi:10.1158/1078-0432.CCR-13-2287.
   PubMed Web of Science ®Google Scholar
• LaFargue CJ, Dal Molin GZ, Sood AK, Coleman RL. Exploring and comparing adverse events between PARP inhibitors. Lancet Oncol. 2019;20(1):e15–e28. doi:10.1016/S1470-2045(18)30786-1.
   PubMed Web of Science ®Google Scholar
• Moore KN, Secord AA, Geller MA, Miller DS, Cloven N, Fleming GF, Wahner Hendrickson AE, Azodi M, DiSilvestro P, Oza AM, et al. Niraparib monotherapy for late-line treatment of ovarian cancer (QUADRA): a multicentre, open-label, single-arm, phase 2 trial. Lancet Oncol. 2019;20(5):636–648. doi:10.1016/S1470-2045(19)30029-4.
   PubMed Web of Science ®Google Scholar
• Moore K, Colombo N, Scambia G, Kim BG, Oaknin A, Friedlander M, Lisyanskaya A, Floquet A, Leary A, Sonke GS, et al. Maintenance olaparib in patients with newly diagnosed advanced ovarian cancer. N Engl J Med. 2018;379(26):2495–2505. doi:10.1056/NEJMoa1810858.
   PubMed Web of Science ®Google Scholar
• Monk BJ, Mirza MR, Vergote I, Li Y, Malinowska I, Gupta D, Graybill WA, Pothuri B, Gonzalez-Martin A. A prospective evaluation of tolerability of niraparib dosing based upon baseline body weight and platelet count: blinded pooled interim safety data from the ENGOT-OV26/PRIMA study. Gynecol Oncol. 2019;154(suppl 1):3–4. doi:10.1016/j.ygyno.2019.04.018.
   PubMedGoogle Scholar
• González Martín A, Pothuri B, Vergote I, DePont Christensen R, Graybill W, Mirza MR, McCormick C, Lorusso D, Hoskins P, Freyer G, et al. Niraparib in patients with newly diagnosed advanced ovarian cancer. N Engl J Med. 2019;381(25):2391–2402. doi:10.1056/NEJMoa1910962.
   PubMed Web of Science ®Google Scholar
• Coleman RL, Fleming GF, Brady MF, Swisher EM, Steffensen KD, Friedlander M, Okamoto A, Moore KN, Efrat Ben-Baruch N, Werner TL, et al. Veliparib with first-line chemotherapy and as maintenance therapy in ovarian cancer. N Engl J Med. 2019;381(25):2403–2415. doi:10.1056/NEJMoa1909707.
   PubMed Web of Science ®Google Scholar
• Ray-Coquard I, Pautier P, Pignata S, Pérol D, González-Martín A, Berger R, Fujiwara K, Vergote I, Colombo N, Mäenpää J, et al. PAOLA-1 Investigators. Olaparib plus bevacizumab as first-line maintenance in ovarian cancer. N Engl J Med. 2019;381(25):2416–2428. doi:10.1056/NEJMoa1911361.
   PubMed Web of Science ®Google Scholar
• George A, Kaye S, Banerjee S. Delivering widespread BRCA testing and PARP inhibition to patients with ovarian cancer. Nat Rev Clin Oncol. 2017;14(5):284–296. doi:10.1038/nrclinonc.2016.191.
   PubMed Web of Science ®Google Scholar
• D’Andrea AD. Mechanisms of PARP inhibitor sensitivity and resistance. DNA Repair (Amst). 2018;71:172–176. doi:10.1016/j.dnarep.2018.08.021.
   PubMed Web of Science ®Google Scholar
• Chartron E, Theillet C, Guiu S, Jacot W. Targeting homologous repair deficiency in breast and ovarian cancers: biological pathways, preclinical and clinical data. Crit Rev Oncol Hematol. 2019;133:58–73. doi:10.1016/j.critrevonc.2018.10.012.
   PubMed Web of Science ®Google Scholar
• Hodgson DR, Dougherty BA, Lai Z, Fielding A, Grinsted L, Spencer S, O’Connor MJ, Ho TW, Robertson JD, Lanchbury JS, et al. Candidate biomarkers of PARP inhibitor sensitivity in ovarian cancer beyond the BRCA genes. Br J Cancer. 2018;119(11):1401–1409. doi:10.1038/s41416-018-0274-8.
   PubMed Web of Science ®Google Scholar
• Jiang X, Li X, Li W, Bai H, Zhang Z. PARP inhibitors in ovarian cancer: sensitivity prediction and resistance mechanisms. J Cell Mol Med. 2019;23(4):2303–2313. doi:10.1111/jcmm.14133.
   PubMed Web of Science ®Google Scholar
• Gourley C, Balmaña J, Ledermann JA, Serra V, Dent R, Loibl S, Pujade-Lauraine E, Boulton SJ. Moving from poly (ADP-ribose) polymerase inhibition to targeting DNA repair and DNA damage response in cancer therapy. J Clin Oncol. 2019;37(25):2257–2269. doi:10.1200/JCO.18.02050.
   PubMed Web of Science ®Google Scholar
• Quigley D, Alumkal JJ, Wyatt AW, Kothari V, Foye A, Lloyd P, Aggarwal R, Kim W, Lu E, Schwartzman J, et al. Analysis of circulating cell-free DNA identifies multiclonal heterogeneity of BRCA2 reversion mutations associated with resistance to PARP inhibitors. Cancer Discov. 2017;7(9):999–1005. doi:10.1158/2159-8290.CD-17-0146.
   PubMed Web of Science ®Google Scholar
• Lin KK, Harrell MI, Oza AM, Oaknin A, Ray-Coquard I, Tinker AV, Helman E, Radke MR, Say C, Vo LT, et al. BRCA reversion mutations in circulating tumor DNA predict primary and acquired resistance to the PARP inhibitor rucaparib in high-grade ovarian carcinoma. Cancer Discov. 2019;9(2):210–219. doi:10.1158/2159-8290.CD-18-0715.
   PubMed Web of Science ®Google Scholar
• Kondrashova O, Nguyen M, Shield-Artin K, Tinker AV, Teng NNH, Harrell MI, Kuiper MJ, Ho GY, Barker H, Jasin M, et al. AOCS Study Group. Secondary somatic mutations restoring RAD51C and RAD51D associated with acquired resistance to the PARP inhibitor rucaparib in high-grade ovarian carcinoma. Cancer Discov. 2017;7(9):984–998. doi:10.1158/2159-8290.CD-17-0419.
   PubMed Web of Science ®Google Scholar
• Drakes ML, Stiff PJ. Regulation of ovarian cancer prognosis by immune cells in the tumor microenvironment. Cancers (Basel). 2018;10(9):pii:E302. doi:10.3390/cancers10090302.
   PubMed Web of Science ®Google Scholar
• Hamanishi J, Mandai M, Iwasaki M, Okazaki T, Tanaka Y, Yamaguchi K, Higuchi T, Yagi H, Takakura K, Minato N, et al. Programmed cell death 1 ligand 1 and tumor-infiltrating CD8+ T lymphocytes are prognostic factors of human ovarian cancer. Proc Natl Acad Sci U S A. 2007;104(9):3360–3365. doi:10.1073/pnas.0611533104.
   PubMed Web of Science ®Google Scholar
• Drakes ML, Mehrotra S, Aldulescu M, Potkul RK, Liu Y, Grisoli A, Joyce C, O’Brien TE, Stack MS, Stiff PJ. Stratification of ovarian tumor pathology by expression of programmed cell death-1 (PD-1) and PD-ligand-1 (PD-L1) in ovarian cancer. J Ovarian Res. 2018;11(1):43. doi:10.1186/s13048-018-0414-z.
   PubMedGoogle Scholar
• Zhang L, Conejo-Garcia JR, Katsaros D, Gimotty PA, Massobrio M, Regnani G, Makrigiannakis A, Gray H, Schlienger K, Liebman MN, et al. Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N Engl J Med. 2003;348(3):203–213. doi:10.1056/NEJMoa020177.
   PubMed Web of Science ®Google Scholar
• Anderson KG, Stromnes IM, Greenberg PD. Obstacles posed by the tumor microenvironment to T cell activity: a case for synergistic therapies. Cancer Cell. 2017;31(3):311–325. doi:10.1016/j.ccell.2017.02.008.
   PubMed Web of Science ®Google Scholar
• Zarour HM. Reversing T-cell dysfunction and exhaustion in cancer. Clin Cancer Res. 2016;22(8):1856–1864. doi:10.1158/1078-0432.CCR-15-1849.
   PubMed Web of Science ®Google Scholar
• Hamanishi J, Mandai M, Ikeda T, Minami M, Kawaguchi A, Murayama T, Kanai M, Mori Y, Matsumoto S, Chikuma S, et al. Safety and antitumor activity of anti-PD-1 antibody, nivolumab, in patients with platinum-resistant ovarian cancer. J Clin Oncol. 2015;33(34):4015–4022. doi:10.1200/JCO.2015.62.3397.
   PubMed Web of Science ®Google Scholar
• Omatsu K, Hamanishi J, Katsumata N, Nishio S, Sawada K, Takeuchi S, Aoki D, Fujiwara K, Sugiyama T, Konishi I. Nivolumab versus gemcitabine or pegylated liposomal doxorubicin for patients with platinum-resistant (advanced or recurrent) ovarian cancer: open-label, randomized trial in Japan (NINJA trial). Ann Oncol. 2020;31(suppl. 4):S611. doi:10.1016/j.annonc.2020.08.946.
   Google Scholar
• Varga A, Piha-Paul S, Ott PA, Mehnert JM, Berton-Rigaud D, Morosky A, Yang P, Ruman J, Matei D. Pembrolizumab in patients with programmed death ligand 1-positive advanced ovarian cancer: analysis of KEYNOTE-028. Gynecol Oncol. 2019;152(2):243–250. doi:10.1016/j.ygyno.2018.11.017.
   PubMed Web of Science ®Google Scholar
• Matulonis UA, Shapira-Frommer R, Santin AD, Lisyanskaya AS, Pignata S, Vergote I, Raspagliesi F, Sonke GS, Birrer M, Provencher DM, et al. Antitumor activity and safety of pembrolizumab in patients with advanced recurrent ovarian cancer: results from the phase 2 KEYNOTE-100 study. Ann Oncol. 2019;30(7):1080–1087. doi:10.1093/annonc/mdz135.
   PubMed Web of Science ®Google Scholar
• Johnson ML, Braiteh F, Grilley-Olson JE, Chou J, Davda J, Forgie A, Li R, Jacobs I, Kazazi F, Hu-Lieskovan S. Assessment of subcutaneous vs intravenous administration of anti-PD-1 antibody PF-06801591 in patients with advanced solid tumors: a phase 1 dose-escalation trial. JAMA Oncol. 2019;5(7):999–1007. doi:10.1001/jamaoncol.2019.0836.
   PubMed Web of Science ®Google Scholar
• Infante JR, Braiteh F, Emens LA, Balmanoukian AS, Oaknin A, Wang Y, Liu B, Molinero L, Fasso M, O’Hear C, et al. 2016. Safety, clinical activity and biomarkers of atezolizumab (atezo) in advanced ovarian cancer (OC). Ann Oncol. 27(suppl.6):vi296–vi312. doi:10.1093/annonc/mdw374.
   Google Scholar
• Liu JF, Gordon M, Veneris J, Braiteh F, Balmanoukian A, Eder JP, Oaknin A, Hamilton E, Wang Y, Sarkar I, et al. Safety, clinical activity and biomarker assessments of atezolizumab from a Phase I study in advanced/recurrent ovarian and uterine cancers. Gynecol Oncol. 2019;154(2):314–322. doi:10.1016/j.ygyno.2019.05.021.
   PubMed Web of Science ®Google Scholar
• Disis ML, Taylor MH, Kelly K, Beck JT, Gordon M, Moore KM, Patel MR, Chaves J, Park H, Mita AC, et al. Efficacy and safety of avelumab for patients with recurrent or refractory ovarian cancer: phase 1b results from the JAVELIN solid tumor trial. JAMA Oncol. 2019;5(3):393–401. doi:10.1001/jamaoncol.2018.6258.
   PubMed Web of Science ®Google Scholar
• Postow MA, Sidlow R, Hellmann MD. Immune-related adverse events associated with immune checkpoint blockade. N Engl J Med. 2018;378(2):158–168. doi:10.1056/NEJMra1703481.
   PubMed Web of Science ®Google Scholar
• Kandalaft LE, Odunsi K, Coukos G. Immunotherapy in ovarian cancer: are we there yet? J Clin Oncol. 2019;37(27):2460–2471. doi:10.1200/JCO.19.00508.
   PubMed Web of Science ®Google Scholar
• Zhang L, Chen Y, Li F, Bao L, Liu W. Atezolizumab and bevacizumab attenuate cisplatin resistant ovarian cancer cells progression synergistically via suppressing epithelial-mesenchymal transition. Front Immunol. 2019;10:867. doi:10.3389/fimmu.2019.00867.
   PubMed Web of Science ®Google Scholar
• Liu JF, Herold C, Luo W, Penson R, Horowitz N, Konstantinopoulos P, Castro C, Curtis J, Matulonis UA, Cannistra S, et al. 2018. A phase 2 trial of combination nivolumab and bevacizumab in recurrent ovarian cancer. Ann Oncol. 29(suppl8):viii332–viii358. doi:10.1093/annonc/mdy285.
   Google Scholar
• Wang Z, Sun K, Xiao Y, Feng B, Mikule K, Ma X, Feng N, Vellano CP, Federico L, Marszalek JR, et al. Niraparib activates interferon signaling and potentiates anti-PD-1 antibody efficacy in tumor models. Sci Rep. 2019;9(1):1853. doi:10.1038/s41598-019-38534-6.
   PubMed Web of Science ®Google Scholar
• Jiao S, Xia W, Yamaguchi H, Wei Y, Chen MK, Hsu JM, Hsu JL, Yu WH, Du Y, Lee HH, et al. PARP inhibitor upregulates PD-L1 expression and enhances cancer-associated immunosuppression. Clin Cancer Res. 2017;23(14):3711–3720. doi:10.1158/1078-0432.CCR-16-3215.
   PubMed Web of Science ®Google Scholar
• Tanyi JL, Bobisse S, Ophir E, Tuyaerts S, Roberti A, Genolet R, Baumgartner P, Stevenson BJ, Iseli C, Dangaj D, et al. Personalized cancer vaccine effectively mobilizes antitumor T cell immunity in ovarian cancer. Sci Transl Med. 2018;10(436):436. doi:10.1126/scitranslmed.aao5931.
   Web of Science ®Google Scholar
• Pedersen M, Westergaard MCW, Milne K, Nielsen M, Borch TH, Poulsen LG, Hendel HW, Kennedy M, Briggs G, Ledoux S, et al. Adoptive cell therapy with tumor-infiltrating lymphocytes in patients with metastatic ovarian cancer: a pilot study. Oncoimmunology. 2018;7(12):e1502905. doi:10.1080/2162402X.2018.1502905.
   PubMed Web of Science ®Google Scholar
• Kershaw MH, Westwood JA, Parker LL, Wang G, Eshhar Z, Mavroukakis SA, White DE, Wunderlich JR, Canevari S, Rogers-Freezer L, et al. A phase I study on adoptive immunotherapy using gene-modified T cells for ovarian cancer. Clin Cancer Res. 2006;12(20):6106–6115. doi:10.1158/1078-0432.CCR-06-1183.
   PubMed Web of Science ®Google Scholar
• Zhang Z, Jiang D, Yang H, He Z, Liu X, Qin W, Li L, Wang C, Li Y, Li H, et al. Modified CAR T cells targeting membrane-proximal epitope of mesothelin enhances the antitumor function against large solid tumor. Cell Death Dis. 2019;10(7):476. doi:10.1038/s41419-019-1711-1.
   PubMed Web of Science ®Google Scholar
• Yeku OO, Rafiq S, Koneru M, Purdon TJ, Song M, Wang P, Hendrickson R, Brentjens RJ, Spriggs D. MUC16-directed immunotherapy for ovarian cancer. Clin Cancer Res. 2020;26(suppl. 13):IA21.
   Google Scholar
• Moore KN, Bookman M, Sehouli J, Miller A, Anderson C, Scambia G, Myers T, Taskiran C, Robison K, Maenpaa J, et al. Primary results from IMagyn050/GOG 3015/ENGOT-OV39, a double-blind placebo (pbo)-controlled randomised phase III trial of bevacizumab (bev)-containing therapy ± atezolizumab (atezo) for newly diagnosed stage III/IV ovarian cancer (OC). Ann Oncol. 2020;31(suppl 4):S1161–S1162. doi:10.1016/j.annonc.2020.08.2261.
   Google Scholar
• Kaplan AR, Gueble SE, Liu Y, Oeck S, Kim H, Yun Z, Glazer PM. Cediranib suppresses homology-directed DNA repair through down-regulation of BRCA1/2 and RAD51. Sci Transl Med. 2019;11(492):eaav4508. doi:10.1126/scitranslmed.aav4508.
   PubMed Web of Science ®Google Scholar
• Liu JF, Barry WT, Birrer M, Lee JM, Buckanovich RJ, Fleming GF, Rimel BJ, Buss MK, Nattam SR, Hurteau J, et al. Overall survival and updated progression-free survival outcomes in a randomized phase II study of combination cediranib and olaparib versus olaparib in relapsed platinum-sensitive ovarian cancer. Ann Oncol. 2019;30(4):551–557. doi:10.1093/annonc/mdz018.
   PubMed Web of Science ®Google Scholar
• Mirza MR, Åvall Lundqvist E, Birrer MJ, dePont Christensen R, Nyvang GB, Malander S, Anttila M, Werner TL, Lund B, Lindahl G, et al. Niraparib plus bevacizumab versus niraparib alone for platinum-sensitive recurrent ovarian cancer (NSGO-AVANOVA2/ENGOT-ov24): a randomised, phase 2, superiority trial. Lancet Oncol. 2019;20(10):1409–1419. doi:10.1016/S1470-2045(19)30515-7.
   PubMed Web of Science ®Google Scholar
• Liu JF, Brady MF, Matulonis UA, Miller A, Kohn EC, Swisher EM, Tew WP, Cloven NG, Muller C, Bender D, et al. A phase III study comparing single-agent olaparib or the combination of cediranib and olaparib to standard platinum-based chemotherapy in recurrent platinum-sensitive ovarian cancer. J Clin Oncol. 2020;38(suppl. 15):6003. doi:10.1200/JCO.2020.38.15_suppl.6003.
   Web of Science ®Google Scholar
• Konstantinopoulos PA, Waggoner S, Vidal GA, Mita M, Moroney JW, Holloway R, Van Le L, Sachdev JC, Chapman-Davis E, Colon-Otero G, et al. Single-arm phases 1 and 2 trial of niraparib in combination with pembrolizumab in patients with recurrent platinum-resistant ovarian carcinoma. JAMA Oncol. 2019;5(8):1141–1149. doi:10.1001/jamaoncol.2019.1048.
   PubMed Web of Science ®Google Scholar
• Lee J, Annunziata CM, Houston N, Kohn EC, Lipkowitz S, Minasian L, Nichols E, Trepel J, Trewhitt K, Zia F, et al. 2018. A phase 2 study of durvalumab, a PD-L1 inhibitor and olaparib in recurrent ovarian cancer (OvCa). Ann Oncol. 29(suppl.8):viii332–viii358. doi:10.1093/annonc/mdy285.
   Google Scholar
• Zimmer AS, Nichols E, Cimino-Mathews A, Peer C, Cao L, Lee MJ, Kohn EC, Annunziata CM, Lipkowitz S, Trepel JB, et al. A phase I study of the PD-L1 inhibitor, durvalumab, in combination with a PARP inhibitor, olaparib, and a VEGFR1-3 inhibitor, cediranib, in recurrent women’s cancers with biomarker analyses. J Immunother Cancer. 2019;7(1):197. doi:10.1186/s40425-019-0680-3.
   PubMedGoogle Scholar
• Penson RT, Drew Y, de Jonge MJA, Hong S, Park YH, Wolfer A, Brown J, Ferguson M, Gore ME, Alvarez RH, et al. 2018. MEDIOLA: a Phase I/II trial of olaparib (PARP inhibitor) in combination with durvalumab (anti-PD-L1 antibody) in pts with advanced solid tumours. Ann Oncol. 29(suppl 8):viii133–viii148. doi:10.1093/annonc/mdy279.
   Google Scholar
• Drew Y, Penson RT, O’Malley DM, Kim J, Zimmermann S, Roxburgh P, Sohn S, Stemmer SM, Bastian S, Ferguson M, et al. Phase II study of olaparib (O) plus durvalumab (D) and bevacizumab (B) (MEDIOLA): initial results in patients (pts) with non-germline BRCA-mutated (non-gBRCAm) platinum sensitive relapsed (PSR) ovarian cancer (OC). Ann Oncol. 2020;31(suppl. 4):S615–S616. doi:10.1016/j.annonc.2020.08.953.
   Google Scholar
• Moore KN, O’Malley DM, Vergote I, Martin LP, Gonzalez-Martin A, Malek K, Birrer MJ. Safety and activity findings from a phase 1b escalation study of mirvetuximab soravtansine, a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), in combination with carboplatin in patients with platinum-sensitive ovarian cancer. Gynecol Oncol. 2018;151(1):46–52. doi:10.1016/j.ygyno.2018.07.017.
   PubMed Web of Science ®Google Scholar
• Moore KN, Vergote I, Oaknin A, Colombo N, Banerjee S, Oza A, Pautier P, Malek K, Birrer MJ. FORWARD I: a Phase III study of mirvetuximab soravtansine versus chemotherapy in platinum-resistant ovarian cancer. Future Oncol. 2018;14(17):1669–1678. doi:10.2217/fon-2017-0646.
   PubMed Web of Science ®Google Scholar
• Moore KN, Oza AM, Colombo N, Oaknin A, Scambia G, Lorusso D, Farias-Eisner R, Banerjee S, Murphy CG, Tanyi JL, et al. 2019. FORWARD I (GOG 3011): a Phase III study of mirvetuximab soravtansine, a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), versus chemotherapy in patients (pts) with platinum-resistant ovarian cancer (PROC). Ann Oncol. 30(suppl5):v403–v434. doi:10.1093/annonc/mdz250.
   Google Scholar
• O’Malley DM, Matulonis UA, Birrer MJ, Castro CM, Gilbert L, Vergote I, Martin LP, Mantia-Smaldone GM, Martin AG, Bratos R, et al. Phase Ib study of mirvetuximab soravtansine, a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), in combination with bevacizumab in patients with platinum-resistant ovarian cancer. Gynecol Oncol. 2020;157(2):379–385. doi:10.1016/j.ygyno.2020.01.037.
   PubMed Web of Science ®Google Scholar
• O’Malley DM, Richardson DL, Vergote IB, Gilbert L, Castro C, Provencher D, Matulonis UA, Mantia-Smaldone G, Martin L, Zweidler-Mckay PA, et al. 2020. Mirvetuximab soravtansine (MIRV), a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), in combination with carboplatin (CARBO) and bevacizumab (BEV): final results from a study in patients (pts) with recurrent platinum sensitive ovarian cancer. Ann Oncol. 31(suppl. 4):S626–S627.
   PubMedGoogle Scholar
• Cheng X, Li J, Tanaka K, Majumder U, Milinichik AZ, Verdi AC, Maddage CJ, Rybinski KA, Fernando S, Fernando D, et al. MORAb-202, an antibody-drug conjugate utilizing humanized anti-human FRα farletuzumab and the microtubule-targeting agent eribulin, has potent antitumor activity. Mol Cancer Ther. 2018;17(12):2665–2675. doi:10.1158/1535-7163.MCT-17-1215.
   PubMed Web of Science ®Google Scholar
• Shimizu T, Fujiwara Y, Yonemori K, Koyama T, Shimomura A, Tamura K, Iwasa S, Jun Sato J, Kitano S, Ikezawa H, et al. First-in-human (FIH) phase 1 (Ph1) study of MORAb-202 in patients (pts) with advanced folate receptor alpha (FRA)-positive solid tumors. J Clin Oncol. 2019;37(suppl 15):5544. doi:10.1200/JCO.2019.37.15_suppl.5544.
   Google Scholar
• de Bono JS, Concin N, Hong DS, Thistlethwaite FC, Machiels JP, Arkenau HT, Plummer R, Jones RH, Nielsen D, Windfeld K, et al. Tisotumab vedotin in patients with advanced or metastatic solid tumours (InnovaTV 201): a first-in-human, multicentre, phase 1-2 trial. Lancet Oncol. 2019;20(3):383–393. doi:10.1016/S1470-2045(18)30859-3.
   PubMed Web of Science ®Google Scholar
• Theunissen JW, Cai AG, Bhatti MM, Cooper AB, Avery AD, Dorfman R, Guelman S, Levashova Z, Migone TS. Treating tissue factor-positive cancers with antibody-drug conjugates that do not affect blood clotting. Mol Cancer Ther. 2018;17(11):2412–2426. doi:10.1158/1535-7163.MCT-18-0471.
   PubMed Web of Science ®Google Scholar
• Mahdi H, Schuster SR, O’Malley DM, McNamara DM, Rangwala RA, Liang S-Y, Jain S, Nicacio L, Chon HS. Phase 2 trial of tisotumab vedotin in platinum-resistant ovarian cancer (innovaTV 208). J Clin Oncol. 2019;37(suppl15):TPS5602. doi:10.1200/JCO.2019.37.15_suppl.TPS5602.
   Google Scholar
• Damelin M, Bankovich A, Bernstein J, Lucas J, Chen L, Williams S, Park A, Aguilar J, Ernstoff E, Charati M, et al. A PTK7-targeted antibody-drug conjugate reduces tumor-initiating cells and induces sustained tumor regressions. Sci Transl Med. 2017;9(372):372. doi:10.1126/scitranslmed.aag2611.
   Web of Science ®Google Scholar
• Sachdev JC, Maitland ML, Sharma M, Moreno V, Boni V, Kummar S, Stringer-Reasor EM, Forero-Torres A, Lakhani NJ, Gibson B, et al. PF-06647020 (PF-7020), an antibody-drug conjugate (ADC) targeting protein tyrosine kinase 7 (PTK7), in patients (pts) with advanced solid tumors: results of a phase I dose escalation and expansion study. J Clin Oncol. 2018;36(suppl 15):5565. doi:10.1200/JCO.2018.36.15_suppl.5565.
   Web of Science ®Google Scholar
• Jackson-Fisher A, Mehra N, Gianani R, Whalen P, Vizcarra P, Deng S, McComish S, Xin X, Powell EL. Protein tyrosine kinase 7 (PTK7) biomarker analysis in patients (pts) treated with PF-06647020, a PTK7 antibody-drug conjugate (ADC), in a phase I dose expansion study. Cancer Res. 2019;79(suppl 13):4035.
   Web of Science ®Google Scholar
• De Witt Hamer PC, Mir SE, Noske D, Van Noorden CJ, Wurdinger T. WEE1 kinase targeting combined with DNA-damaging cancer therapy catalyzes mitotic catastrophe. Clin Cancer Res. 2011;17(13):4200–4207. doi:10.1158/1078-0432.CCR-10-2537.
   PubMed Web of Science ®Google Scholar
• Do K, Wilsker D, Ji J, Zlott J, Freshwater T, Kinders RJ, Collins J, Chen AP, Doroshow JH, Kummar S. Phase I study of single-agent AZD1775 (MK-1775), a Wee1 kinase inhibitor, in patients with refractory solid tumors. J Clin Oncol. 2015;33(30):3409–3415. doi:10.1200/JCO.2014.60.4009.
   PubMed Web of Science ®Google Scholar
• Leijen S, van Geel RM, Sonke GS, de Jong D, Rosenberg EH, Marchetti S, Pluim D, van Werkhoven E, Rose S, Lee MA, et al. Phase II study of WEE1 inhibitor AZD1775 plus carboplatin in patients with TP53-mutated ovarian cancer refractory or resistant to first-line therapy within 3 months. J Clin Oncol. 2016;34:4354–4361. doi:10.1200/JCO.2016.67.5942.
   PubMed Web of Science ®Google Scholar
• Hamilton E, Falchook GS, Wang JS, Fu S, Oza A, Karen S, Imedio ER, Kumar S, Ottesen L, Mugundu GM, et al. 2019. Phase Ib study of adavosertib in combination with olaparib in patients with refractory solid tumors: dose escalation. Cancer Res. 79(suppl 13):CT025.
   Web of Science ®Google Scholar
• André F, Ciruelos E, Rubovszky G, Campone M, Loibl S, Rugo HS, Iwata H, Conte P, Mayer IA, Kaufman B, et al. SOLAR-1 Study Group. Alpelisib for PIK3CA-mutated, hormone receptor-positive advanced breast cancer. N Engl J Med. 2019;380:1929–1940. doi:10.1056/NEJMoa1813904.
   PubMed Web of Science ®Google Scholar
• Konstantinopoulos PA, Barry WT, Birrer M, Westin SN, Cadoo KA, Shapiro GI, Mayer EL, O’Cearbhaill RE, Coleman RL, Kochupurakkal B, et al. Olaparib and α-specific PI3K inhibitor alpelisib for patients with epithelial ovarian cancer: a dose-escalation and dose-expansion phase 1b trial. Lancet Oncol. 2019;20(4):570–580. doi:10.1016/S1470-2045(18)30905-7.
   PubMed Web of Science ®Google Scholar
• Patnaik A, Haluska P, Tolcher AW, Erlichman C, Papadopoulos KP, Lensing JL, Beeram M, Molina JR, Rasco DW, Arcos RR, et al. A first-in-human phase i study of the oral p38 MAPK inhibitor, ralimetinib (LY2228820 dimesylate), in patients with advanced cancer. Clin Cancer Res. 2016;22(5):1095–1102. doi:10.1158/1078-0432.CCR-15-1718.
   PubMed Web of Science ®Google Scholar
• Vergote I, Heitz F, Buderath P, Powell M, Sehouli J, Lee CM, Hamilton A, Fiorica J, Moore KN, Teneriello M, et al. A randomized, double-blind, placebo-controlled phase 1b/2 study of ralimetinib, a p38 MAPK inhibitor, plus gemcitabine and carboplatin versus gemcitabine and carboplatin for women with recurrent platinum-sensitive ovarian cancer. Gynecol Oncol. 2020;156(1):23–31. doi:10.1016/j.ygyno.2019.11.006.
   PubMed Web of Science ®Google Scholar
• Parmar K, Kochupurakkal BS, Lazaro JB, Wang ZC, Palakurthi S, Kirschmeier PT, Yang C, Sambel LA, Färkkilä A, Reznichenko E, et al. The CHK1 inhibitor prexasertib exhibits monotherapy activity in high-grade serous ovarian cancer models and sensitizes to PARP inhibition. Clin Cancer Res. 2019;25(20):6127–6140. doi:10.1158/1078-0432.CCR-19-0448.
   PubMed Web of Science ®Google Scholar
• Lee JM, Nair J, Zimmer A, Lipkowitz S, Annunziata CM, Merino MJ, Swisher EM, Harrell MI, Trepel JB, Lee MJ, et al. Prexasertib, a cell cycle checkpoint kinase 1 and 2 inhibitor, in BRCA wild-type recurrent high-grade serous ovarian cancer: a first-in-class proof-of-concept phase 2 study. Lancet Oncol. 2018;19(2):207–215. doi:10.1016/S1470-2045(18)30009-3.
   PubMed Web of Science ®Google Scholar
• Angius G, Tomao S, Stati V, Vici P, Bianco V, Tomao F. Prexasertib, a checkpoint kinase inhibitor: from preclinical data to clinical development. Cancer Chemother Pharmacol. 2020;85(1):9–20. doi:10.1007/s00280-019-03950-y.
   PubMed Web of Science ®Google Scholar
• Brown EJ, Baltimore D. ATR disruption leads to chromosomal fragmentation and early embryonic lethality. Genes Dev. 2000;14(4):397–402.
   PubMed Web of Science ®Google Scholar
• Foote KM, Nissink JWM, McGuire T, Turner P, Guichard S, Yates JWT, Lau A, Blades K, Heathcote D, Odedra R, et al. Discovery and characterization of AZD6738, a potent inhibitor of ataxia telangiectasia mutated and Rad3 related (ATR) kinase with application as an anticancer agent. J Med Chem. 2018;61(22):9889–9907. doi:10.1021/acs.jmedchem.8b01187.
   PubMed Web of Science ®Google Scholar
• Bradbury A, Hall S, Curtin N, Drew Y. Targeting ATR as cancer therapy: a new era for synthetic lethality and synergistic combinations? Pharmacol Ther. 2020;207:107450. doi:10.1016/j.pharmthera.2019.107450.
   PubMed Web of Science ®Google Scholar
• Gorecki L, Andrs M, Rezacova M, Korabecny J. Discovery of ATR kinase inhibitor berzosertib (VX-970, M6620): clinical candidate for cancer therapy. Pharmacol Ther. 2020 Feb 26;210:107518. doi:10.1016/j.pharmthera.2020.107518.
   PubMed Web of Science ®Google Scholar
• Thomas A, Redon CE, Sciuto L, Padiernos E, Ji J, Lee MJ, Yuno A, Lee S, Zhang Y, Tran L, et al. Phase I study of ATR inhibitor M6620 in combination with topotecan in patients with advanced solid tumors. J Clin Oncol. 2018;36(16):1594–1602. doi:10.1200/JCO.2017.76.6915.
   PubMed Web of Science ®Google Scholar
• Konstantinopoulos PA, Wahner Hendrickson AE, Penson RT, Doyle A, Kohn EC, Duska RL, Crispens MA, Olawaiye AB, Winer IS, Barroilhet LM, et al. Randomized phase 2 (RP2) study of ATR inhibitor M6620 in combination with gemcitabine versus gemcitabine alone in platinum-resistant high grade serous ovarian cancer (HGSOC). Ann Oncol. 2019;30(suppl 5):v897. doi:10.1093/annonc/mdz394.057.
   PubMedGoogle Scholar